The TSJCI Governance Committee was established in 2021. The committee is chaired by an external chairperson, jointly appointed by the CEO of St James’s Hospital and the Provost of Trinity College. The principal functions of the Governance Committee are to promote, encourage and foster the establishment and maintenance of high standards and best practice in the conduct and delivery of research, cancer care, cancer clinical trials and education, and to develop and oversee the implementation of the TSJCI strategy for approval by the boards and for delivery by the executive. The committee carries out its work under an agreed term of reference (ToR). The Committee Chair provides update and progress reports to the Board of St James’s Hospital (via the CEO) and to the Board of TCD (via the Provost).
The TSJCI Executive Committee, under the leadership of and chaired by the TSJCI Co-Directors, held its first meeting in July 2021. The role of the executive committee is to deliver on the objectives and targets outlined in the TSJCI strategy. The committee has a broad membership with representation across the pillars of TSJCI and stakeholders from Trinity College Dublin, St James’s Hospital and St Luke’s Radiation Oncology Network. The Executive Committee reports via the Directors to the Governance Committee. The TSJCI Pillar Leads (Clinical, Cancer Clinical Trials, Research and Education) work through the executive and their organisations to implement the strategy for the TSJCI.
The TSJCI External Advisory Board (EAB) membership was established in 2022. The EAB has representation from leaders in the field of scientific and clinical research, medicine, education, management, nursing and patient advocacy and involvement. The role of the EAB is to provide strategic advice to the TSJCI Executive Committee.
The Academic and Medical Directors, Prof Maeve Lowery and Prof John Kennedy, were appointed by the boards of TCD and SJH in 2021. The Co-Directors provide leadership in setting and delivering the agreed strategic direction of the TSJCI, reporting on progress and challenges to the Governance Committee, CEO of SJH, and Provost of TCD.
The TSJCI Pillar Leads (Clinical, Cancer Clinical Trials, Research and Education) work through the executive and their organisations to implement the strategy for the TSJCI.
The TSJCI Programme Office team, led by the TSJCI Programme Manager and Directors, oversees and supports the delivery of a variety of work streams including accreditation, strategic partnerships, patient partnership and involvement, infrastructure, communications, quality, clinical trials and audit. The Programme Office is responsible for the implementation of the TSJCI strategy, and collation and submission of evidence for re-accreditation by OECI in 2024 in collaboration with the directors, pillar leads, multidisciplinary teams at SJH, SLRON, CHI, and TCD, and patients.
